Lund, Sweden, September 24, 2026. Hansa Biopharma AB (publ), “Hansa” (Nasdaq Stockholm: HNSA), announced today the election of Shannon Campbell and Gregory Perry to Hansa's Board of Directors, effective September 22, 2026 until the end of the next Annual General Meeting.

Peter Nicklin, Chairman of the Board, said: “Shannon Campbell and Gregory Perry bring valuable additional expertise to Hansa’s Board. Shannon’s proven commercial and product-launch experience in US, combined with Gregory’s deep expertise in finance, governance and value-creating strategic transactions, will support the continued execution of our strategy and the creation of long-term value for patients and shareholders.”

Shannon Campbell has served as Executive Vice President and Chief Commercial Officer of Merus, where she led the global commercial organization and commercialization strategy through the company's acquisition by Genmab. Prior to Merus, Shannon held senior commercial leadership positions at Novartis and Bayer, where she was responsible for multi-billion-dollar oncology portfolios and commercial operations. Throughout her career, she has led the successful commercialization of over 30 specialty brands, including 15 launches in major global markets. She holds a B.S., Physical Therapy, Ithaca College, Ithaca, NY and has completed executive education programs in leadership, strategy, and finance at the University of Michigan Ross School of Business, IMD, Harvard Business School, and Wharton.

Gregory Perry has served as Chief Financial Officer of Merus, where he led financing activities and supported the company's strategic development through its acquisition by Genmab. Prior to Merus, Gregory served as Chief Financial Officer of several publicly listed biotechnology companies, including Finch Therapeutics, Novelion Therapeutics and ImmunoGen. Throughout his career, he has raised more than $1 billion in public and private financings and played key roles in numerous mergers, acquisitions, and corporate restructurings. He holds a B.A., Economics & Political Science, Amherst College.

Concurrent with these Board changes, Michael Bologna, Chief Investment Officer at NovaQuest Capital Management, will step down from his position as a member of the Board of Directors. The Company would like to thank Michael for his valuable insights and contributions to the Board's work.

--- ENDS ---

Contacts for more information:

Adam Cutler, Chief Financial Officer
IR@hansabiopharma.com

Kerstin Falck, VP Global Corporate Affairs
[email protected]

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa’s proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company’s portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at  www.hansabiopharma.com  and follow us on LinkedIn.

©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, Idefirix^®, and Idefirix flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.